The company said results from a randomized Phase 2 trial of 102 patients demonstrated that women with metastatic triple-negative breast cancer (TNBC) lived significantly longer when receiving trilaciclib and chemotherapy compared with women receiving chemotherapy alone.
G1’s stock jumped 35% to $26.59 a share on strong volume.
“Triple-negative breast cancer is the most aggressive type of breast cancer, and women diagnosed with metastatic TNBC need new treatment options," said CEO Mark Velleca. "We look forward to sharing these data with regulators, as well as presenting findings from this trial at a medical meeting later this year.”
G1 is a clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina.
The company expects to submit marketing applications in the US and Europe in 2020 to use trilaciclib to treat small-cell lung cancer.
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham